Prior studies indicate that the CXCR2 antagonist, SCH-527123, decreased Erk and Akt activation in colorectal cancer cells [34] and that CXCR2 knockdown reduced Erk activation in ovarian cancer cells [9]. This evidence concerns the gene AKT1 and colorectal cancer.